University of California

Merck Sharp + Dohme Corp.

Millennium Pharmaceuticals Limited

Memorial Sloan Kettering Cancer Center

Sloan-kettering Institute for Cancer Research

Memorial Hospital for Cancer and Allied Diseases

Xingyue He

Gregory J Hannon

Lin He

Peter S Linsley

Michel Sadelain

Scott William Lowe

Lee Lim

Julja Burchard

Jorge Mansilla-Soto

Aimee L Jackson

Michele A Cleary

Jill F Magnus

Yong Jin Choi

Sascha P Haubner

Chao-Po Lin

Gary Shapiro

The presently disclosed subject matter provides for chimeric receptors that target ADGRE2 and chimeric receptors that target CLEC12A. The presently disclosed subject matter also provides for cells comprising the ADGRE2-targeted chimeric receptors, cells comprising the CLEC12A-targeted chimeric receptors, and cells comprising the ADGRE2-targeted chimeric receptors and the CLEC12A-targeted chimeric receptors. The presently disclosed subject matter further provides uses of such cells for treating tumors, e.g., AML.

Chimeric receptors targeting ADGRE2 and/or CLEC12A and uses thereof

The present disclosure provides a method of generating an induced pluripotent stem cell; as well as nucleic acids and genetically modified host cells useful in generating iPSCs. The present disclosure provides iPSCs, and methods of use of same.

Compositions and methods for generating induced pluripotent stem cells

In one aspect, the invention generally relates to use of miR-34 as a biomarker to estimate TP53 function in a cell. In another aspect, the invention generally relates to multiple uses of miR-34 and siRNAs functionally and structurally related to miR-34 for the treatment of cancer.

Methods of using MIR34 as a biomarker for TP53 functional status

Growing community of inventors

Cambridge, MA, United States of America

Xingyue He